TAG:
smear test
“September 20, 1999 Intelligence: Late Breaking Lab News”
Here’s an interesting company to keep an eye on. Abaton.com, based in Minneapolis, is one of the early entrants in the race to offer web-based clinical network solutions at the point of care. Centrex Clinical Laboratories, Inc. of Utica, New York is purchasing Abat…
Finally: Respect for Cytyc As Aetna OKs ThinPrep®
CEO SUMMARY: Here’s an important development in the battle to get the healthcare community to accept new technology for the preparation of Pap smears. Aetna/U.S. Healthcare announced that it would cover the monolayer preparation tests offered by Cytyc and AutoCyte. Aetna’s decision ma…
Surprise Merger Changes Cytology Marketplace
CEO SUMMARY: Expect the merger of AutoCyte, Inc. and NeoPath, Inc. to inaugurate a new market cycle for automated cytology systems. FDA approval of AutoCyte’s liquid preparation system, called PREP™, sets the stage for intensified marketing battles between the AutoCyte/NeoPath consort…
Kaiser Plans Widespread Use For Pap Technology
WITHIN THE HMO INDUSTRY, Kaiser Permanente is highly respected for its thorough research into the clinical efficacy and economic cost of new healthcare technologies. That is the reason why Kaiser’s decision to adopt NeoPath, Inc.’s automated cytology technology…
AutoCyte Moves One Step Closer To FDA Approval
CEO SUMMARY: Until now, AutoCyte has kept a relatively quiet presence in the automated cytology marketplace. That may soon change as the FDA takes action on the company’s PREP™ and SCREEN™ products. AutoCyte expects these products will boost productivity and quality in cytology labs…
AccuMed, AutoCyte, Cytyc, MorphoMetrix, Neuromedical, NeoPath
Automated Cytology Update As predicted by THE DARK REPORT, the field of automated cytology has become a boiling pot, filled with controversy and change. Profits are meager. As we expected, the major issue revolves around the cost of this enhanced technology versus the measurable…
AutoPap System Cleared For Primary Screening
CEO SUMMARY: It is time for pathologists and cytologists to buckle their safety belts. The marketplace for automated cytology is entering a new cycle of rapid change. NeoPath’s AutoPap System is now poised to demonstrate that it is economical and clinically viable. Expect continual impr…
Automated Pap Screening Gains Recommendation
CEO SUMMARY: Automated cytology technology received a big boost when the FDA’s advisory panel voted to recommend that the FDA approve, with conditions, NeoPath’s AutoPap® System as a primary Pap Smear Screener. The company still awaits final FDA approval on this matter….
Neuromedical’s PAPNET® Undergoing Enhancement
CEO SUMMARY: Financial pressures and a falling stock price impelled Neuromedical Systems, Inc. to revamp its sales and marketing plan for the PAPNET® System. During 1998, expect a new sales approach that supports a product with enhanced capabilities. Neuromedical is developing overseas m…
Automated Cytology Technology To Come Into Its Own In 1998
CEO SUMMAR…
CURRENT ISSUE
Volume XXXII, No. 6 – April 21, 2025
Now that a federal judge has vacated the FDA’s LDT rule, The Dark Report analyzes the judgement and notes the various steps the FDA could take in response. Also, lab testing at pharmacies is proving to be less successful than was once anticipated.
See the full table of contentsHow Much Laboratory Business Intelligence Have You Missed?
Lab leaders rely on THE DARK REPORT for actionable intelligence on important developments in the business of laboratory testing. Maximize the money you make-and the money you keep! Best of all, it is released every three weeks!
Sign up for TDR Insider
Join the Dark Intelligence Group FREE and get TDR Insider FREE!
Never miss a single update on the issues that matter to you and your business.